Human monoclonal anti-PD-L1 antibodies and methods of use
US9828434B2 · kind B2 · utility
7Cited by
19References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 4, 2013 |
| Grant date | Nov 28, 2017 |
| Priority date | — |
| Expiry date | Oct 4, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.